Evidence map›Paper›PMID 39906666›Full record

ArticleFrontiers in oncology2024

Rowan Abdelbary, Manon Ragheb, Shereen A El Sobky, Nagwa El-Badri, Nourhan Aboud, Ahmed Tawheed, Asmaa Gomaa, Mona Zidan, Ramy K Aziz, Abd Elrahman Abouzid and 7 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rowan AbdelbaryBiotechnology Graduate Program, American University in New Cairo, Cairo, Egypt.
Manon RaghebBiotechnology Graduate Program, American University in New Cairo, Cairo, Egypt.
Shereen A El SobkySchool of Medicine, Newgiza University (NGU), Giza, Egypt.
Nagwa El-BadriCenter of Excellence for Stem Cells and Regenerative Medicine, Zewail City of Science and Technology, Giza, Egypt.
Nourhan AboudSchool of Medicine, Newgiza University (NGU), Giza, Egypt.
Ahmed TawheedEndemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Asmaa GomaaNational Liver Institute, Menoufia University, Menoufia, Egypt.
Mona ZidanMicrobiology and Immunology Research Program, Children's Cancer Hospital Egypt 57357, Cairo, Egypt.
Ramy K AzizMicrobiology and Immunology Research Program, Children's Cancer Hospital Egypt 57357, Cairo, Egypt.
Abd Elrahman AbouzidCenter of Excellence for Stem Cells and Regenerative Medicine, Zewail City of Science and Technology, Giza, Egypt.
Radwa Ayman SalahCenter of Excellence for Stem Cells and Regenerative Medicine, Zewail City of Science and Technology, Giza, Egypt.
Mohamed El-KassasEndemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Imam WakedNational Liver Institute, Menoufia University, Menoufia, Egypt.
Ahmed MoustafaBiotechnology Graduate Program, American University in New Cairo, Cairo, Egypt.
Injie Omar FawzySchool of Medicine, Newgiza University (NGU), Giza, Egypt.
Nada El-Ekiaby *School of Medicine, Newgiza University (NGU), Giza, Egypt.
Ahmed Ihab Abdelaziz *School of Medicine, Newgiza University (NGU), Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The role of miRNAs in regulating variable molecular functions has been sought by scientists for its promising utility in regulating the immune response and, hence, in treating various diseases. In hepatocellular carcinoma (HCC) specifically, a reduction in the number and efficiency of circulating and intrahepatic natural killer (NK) cells has been reported. Our project aims to investigate the role of Methods: To achieve our aim, we isolated NK cells from the whole blood of 86 patients with HCC and 23 healthy controls. We assessed the expression profile of Results: Our results have indicated that Conclusion: In conclusion, we report

Indexed as

granzymes (GrB)hepatocellular carcinoma (HCC)interferon-gamma (IFN-gamma)microRNAs (miRNAs)miR-216a-3pnatural killer (NK) cellsperforins (PRF)tumor necrosis factor-alpha (TNF-alpha)

Identifiers

PMID39906666
PMCPMC11790671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.